Related Experiment Video
Updated: Aug 9, 2026
The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Gene array studies in renal neoplasia
1Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA. john.higgins@stanford.edu
Abstract:
Renal cell carcinoma (RCC) is comprised of several distinct histologic subtypes many of which have characteristic cytogenetic abnormalities. The molecular pathogenesis of some of these neoplasms is beginning to be elucidated. Yet renal cell carcinoma is often discovered at an advanced clinical stage and effective pharmacologic therapies for this disease remain to be discovered. For these reasons, renal cell carcinoma is ideally suited to the genome scale investigation made possible by DNA microarrays. A number of DNA array studies of renal cell carcinoma have been published. Renal cell carcinomas have also been studied by array based comparative genomic hybridization. The purpose of this review will be to summarize these studies, to compare the results of the different studies, and to suggest future areas of investigation with a particular emphasis on clinically relevant advances.
Insights
Genomic studies using DNA microarrays are crucial for understanding renal cell carcinoma (RCC) subtypes and developing new therapies. This review summarizes current research and highlights future directions for effective treatments.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Renal cell carcinoma (RCC) comprises diverse histologic subtypes, often with distinct cytogenetic abnormalities.
- The molecular underpinnings of some RCC subtypes are increasingly understood.
- RCC is frequently diagnosed at advanced stages, necessitating novel pharmacologic treatments.
Purpose of the Study:
- To review and synthesize findings from DNA microarray and array-based comparative genomic hybridization studies in RCC.
- To compare results across different genomic studies of renal cell carcinoma.
- To identify promising future research avenues for clinically relevant advances in RCC treatment.
Main Methods:
- Review of published DNA array studies on renal cell carcinoma.
- Analysis of array-based comparative genomic hybridization data for RCC.
- Comparative analysis of genomic alterations across various RCC subtypes.
Main Results:
- Multiple DNA array studies have investigated genomic alterations in renal cell carcinoma.
- Array-based comparative genomic hybridization has provided insights into RCC pathogenesis.
- Genomic data reveals characteristic abnormalities in distinct RCC subtypes.
Conclusions:
- Genome-scale investigations are vital for advancing the understanding and treatment of renal cell carcinoma.
- Comparative analysis of genomic studies can reveal consistent and novel findings.
- Future research should focus on translating genomic discoveries into effective clinical therapies for RCC.
More Related Videos
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:34DNA Microarrays